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Accepted 1 September 2020; Published online 30 September 2020AbstractObjectives: The aim of this study is to propose an approach for developing trustworthy recommendations as part of urgent responses
(1e2 week) in the clinical, public health, and health systems fields.
Study Design and Setting: We conducted a review of the literature, outlined a draft approach, refined the concept through iterative
discussions, a workshop by the Grading of Recommendations Assessment, Development and Evaluation Rapid Guidelines project group,
and obtained feedback from the larger Grading of Recommendations Assessment, Development and Evaluation working group.
Results: A request for developing recommendations within 2 week is the usual trigger for an urgent response. Although the approach
builds on the general principles of trustworthy guideline development, we highlight the following steps: (1) assess the level of urgency; (2)
assess feasibility; (3) set up the organizational logistics; (4) specify the question(s); (5) collect the information needed; (6) assess the ad-
equacy of identified information; (7) develop the recommendations using one of the 4 potential approaches: adopt existing recommenda-
tions, adapt existing recommendations, develop new recommendations using existing adequate systematic review, or develop new
recommendations using expert panel input; and (8) consider an updating plan.
Conclusion: An urgent response for developing recommendations requires building a cohesive, skilled, and highly motivated multidis-
ciplinary team with the necessary clinical, scientific, and methodological expertise; adapting to shifting needs; complying with the princi-
ples of transparency; and properly managing conflicts of interest.  2020 The Author(s). Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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The development of practice guideline recommenda-
tions requires a complex interplay of many participants
and involves various tasks including setting priorities,scoping the remit of the guideline, identifying an expert
panel group, and managing conflicts of interest [1,2]. The
most time-consuming tasks are the identification, synthesis,
assessment, and presentation of the evidence in ways that
allow the guideline groups to formulate recommendations.
Box 1 Levels of urgency for developing
recommendations
Ultra-short emergency response: 1e2 h
Urgent response: 1e2 wk
Rapid response: up to 3 mo
Routine response: more than 3 mo
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Key findings
 We propose an approach for developing trust-
worthy recommendations as part of an urgent
response (1e2 weeks).
What this adds to what was known?
 The proposed alternatives are: adopting or adapting
existing recommendations; using existent system-
atic reviews to develop new recommendations;
and, relying on expert panel input to develop new
recommendations.
What is the implication and what should change
now?
 It is critical to leverage collaborations, capabilities,
and resources that allow for rapid assessment of
adequate information to support recommendation
development.
Over the last 2 decades, the Grading of Recommendations
Assessment, Development and Evaluation (GRADE) work-
ing group has developed a systematic and transparent
approach to creating evidence-informed practice guidelines
that facilitate this. The method has been applied across the
clinical, public health, and health systems fields [3e5].
Some situations raise the need for urgent recommenda-
tions to support the interventions of clinicians, public
health practitioners, and policymakers, for example, to
address the COVID-19 pandemic [6,7]. Under such circum-
stances, developing trustworthy recommendations in a suf-
ficiently short timeframe is essential but can be challenging
in rapidly changing contexts. Groups producing guidelines
specifically need to balance the need for developing a
timely response with the need to ensure the trustworthiness
of their advice.
The World Health Organization (WHO) defined two
types of guidelines developed in response to an emergency
or urgent need: emergency (rapid response) guidelines (pro-
duced within hours to days) and rapid advice guidelines [8].
Thayer and Schunemann [6] defined four levels of urgency
for developing recommendations: ultra-short emergency
response (1e2 hours), urgent response (1e2 weeks), rapid
response (1e3 months), and routine response (more than
3 months) (Box 1). Although more detailed advice exists
for routine [1] and rapid responses, so far there is no formal
guidance on how to apply GRADE in situations requiring
urgent responses [6,9].
The objective of this paper is to propose an approach for
developing trustworthy recommendations as part of urgent
responses (1e2 weeks) in the clinical, public health, and
health systems fields.
E.A. Akl et al. / Journal of Clin2. Methods
The target audience for the proposed approach are
guideline developers. We consider the timeframe from the
perspective of the guideline developer, that is, the starting
point for the approach is the receipt of a request for devel-
oping recommendations (if applicable), while the finishing
point is the submission of guidance to the requesting orga-
nization. We use the WHO definition of guidelines as ‘‘sys-
tematically developed evidence-based statements which
assist providers, recipients and other stakeholders to make
informed decisions about appropriate health interventions’’
[10].
We developed this approach as members of the GRADE
Rapid Guidelines project group. The GRADE Rapid Guide-
lines project group includes 31 members of the GRADE
working group (gradeworkinggroup.org). These members
collectively have expertise in preclinical, clinical, and
epidemiological primary research, in modeling, in evidence
synthesis (including systematic reviews and rapid reviews),
and in trustworthy practice guideline development. This
expertise spans the breadth fields of clinical, public health,
and health policy. The development of the approach started
in May 2016, and was based on reviewing selected relevant
research (some of which was conducted by members of the
GRADE Rapid Guidelines project group) [6,11e13], itera-
tive discussions within the project group reflecting on the
members’ experiences, informal consensus process, and
feedback from the larger GRADE working group.
In terms of the review of selected relevant research, we
first considered the findings of a 2018 systematic survey of
methods manuals and published guidelines that were devel-
oped in a shortened timeframe [12]. The review found that
rapid guidelines were usually commissioned to address
emergencies, rapid increases in the incidence or severity
of a condition emerging new evidence for a specific treat-
ment. Overall, there was no consensus on the methods for
developing rapid guidance or on the timeframe for develop-
ment, ranging from 1 to 13 months, when reported. Second,
we considered the findings of an interview of guideline de-
velopers about key aspects for rapid guideline development
[11]. Third, we discussed published and unpublished exam-
ples of recommendations developed in response to rapid or
urgent needs, with a focus on understanding how standard
processes were modified [7,13e16].
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included in the approach based on iterative discussions dur-
ing conference calls and a workshop by the project group
(Rome, Italy, April 27, 2017). Members of the project
group also drew on their experiences with developing rec-
ommendations in response to rapid or urgent needs
[17e19]. Finally, the GRADE working group approved this
paper using its expedited publication approval process,
developed in light of the COVID-19 pandemic, and the
need for development of trustworthy recommendations
for its management internationally as part of urgent
responses.3. Results
The project group agreed to build the urgent response
approach on the commonly accepted principles of standard
guideline development (e.g., conflict of interest manage-
ment) [1,2]. The group also agreed that the urgent response
approach can also build on the GIN-McMaster guideline
development checklist extension for rapid recommenda-
tions (see table here: https://bit.ly/rapidGDC) [11]. Ideally,
the process should include the conduct of a rapid review,
whenever feasible. However, and given the major chal-
lenges with feasibility, in the subsequent sections we did
not consider a rapid review as an option.
The proposed approach assumes adherence to the
criteria for applying or using GRADE [20]. These criteria
include giving explicit consideration to the GRADE factors
for determining the direction and strength of a recommen-
dation and, ideally, using GRADE Evidence to Decision
(EtD) frameworks and tables [21]. Under standard guide-
line development conditions, the EtD table is populated
by evidence (typically from a systematic review) for a num-
ber of factors (the health effects of the interventions of in-
terest, values and preferences, certainty of evidence,
resource use, impact on equity, acceptability, and feasi-
bility). The panelists review the evidence for each factor,
then make judgments for those factors in relation to the in-
terventions of interest, before deciding on the strength and
direction for the recommendation [21].
In terms of sources of evidence, systematic reviews may
not be feasible given the timeframe of 1e2 weeks for the
complete recommendation development process. If, in spite
of this tight timeframe, the guideline developers find it
feasible to conduct a rapid review, the reviewers could refer
to the Interim Guidance from the Cochrane Rapid Reviews
Methods Group [22]. In addition, the guideline developers
may consider a timely publication of the systematic review,
including coordination with the coordinating organization/
funder, reviewers, and journal [23]. The proposed approach
offers the alternatives listed at the bottom of Fig. 1, which
are based on the use of existing guidelines and existent sys-
tematic reviews (discussed in more detail below).The following paragraphs discuss the steps of the urgent
response approach and assume that existing and adequate
guidelines and systematic reviews, but not new rapid re-
views, are being considered. However, if a rapid review is
performed it may be added at step 5 in this process. We pro-
vide illustrative examples of urgent situations related to
environmental exposures and to the COVID-19 pandemic.
3.1. Assess the level of urgency
The purpose of this first step is to confirm that the
response in developing the recommendation should be an
‘‘urgent’’ one, as opposed to ‘‘emergent’’ or ‘‘rapid’’ (see
Box 1). Although there is no tool specifically developed
for that purpose, one can use tools such as the WHO rapid
risk assessment of acute public health events [24]. Risk
assessment includes the assessment of the likelihood of
the occurrence of a hazard causing an adverse event, as well
as the likely magnitude of the consequences of the event
over a specified period.
3.2. Assess feasibility
It is important for the guideline developers to assess the
feasibility of meeting the ‘‘urgent’’ timeframe (i.e.,
1e2 weeks). Aspects to be considered include the
following: (1) the number and complexity of questions
and comparisons; (2) the expected amount of work needed
for collecting the literature; (3) the number of team mem-
bers available to contribute to the different tasks; (4) sour-
ces of funding that can be promptly tapped to support the
urgent response; (5) the availability of adequate coordina-
tion capacity; (6) the panelists who can be summoned to
contribute to collecting the needed information, panel dis-
cussion, and peer review in a very intensive manner; and
(7) the political and institutional support to expedite the
administrative processdcollaboratively with the relevant
endorsing bodies (particularly the approval of the final
product and if needed, of the dissemination and implemen-
tation strategies), if applicable.
3.3. Set up the organizational logistics
As the guideline developers start working with the re-
questors on specifying the questions (see next section), it
is important to set up the organizational logistics for the
project. Forming a steering group with executive power that
would meet frequently (e.g., at least on a daily basis) to
ensure the progress of the project and the compliance with
the timeline is key. Similarly, the steering group should
involve methodologists with prior experience in developing
recommendations as part of urgent or rapid responses. Also,
in the context of international collaboration, having mem-
bers from different time zones can help ensure the ability
to sustain project workflow.
Starting on day 1, the steering group should identify and
quickly recruit members of the different groups (including
Fig. 1. Steps involved in urgent guideline development.
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commitment to the expected tasks with a clear timeline and
schedule. However, it might be challenging to recruit stake-
holders (particularly patients’ representatives) in the
context of a rapid response (e.g., in the middle of a
pandemic). Building on existing networks of stakeholders
or having a roster of stakeholders willing to serve as pan-
elists when needed can be helpful. The aim should be
meaningful and equitable multi-stakeholder engagement
[25].
Similarly, when applicable, the steering group needs to
prospectively liaise closely with the organization’s over-
sight and quality committee to ensure compliance with
quality requirements. The steering group should start as
early as possible drafting the final report and fill in its
different sections as the information becomes available, to
expedite its submission and later publication. Other impor-
tant logistics include a streamlined communication plan
with the different groups involved, with the goal of mini-
mizing email burden; and reliable and easy to use document
sharing and online meeting platforms. Ideally, the organiza-
tion should have in place a ‘‘preparedness plan’’ to mount
an urgent response for developing recommendations (with
the appropriate processes and tools).3.4. Specify the question(s)
To make the process feasible, the guideline developers
should work with the requestor to ensure the guideline’s
scope is reasonably narrow. In addition, the guideline de-
velopers should ensure the questions are specific and well
defined, for example, using the PICO (Population,Intervention, Comparator, Outcome) or PECO (Population,
Exposure, Comparator, Outcome) frameworks for interven-
tions and exposures respectively [26,27]. Even within the
PICO or PECO frameworks, additional specificity (narrow-
ing the scope) when defining the population, intervention,
or exposure may facilitate the urgent development process.
Annex 1 provides a brief description and examples of the
elements of the PICO and PECO questions.
Prioritizing outcomes is an essential step of the guide-
line development process. However, it can be time
consuming and not feasible under urgent conditions.
Ideally, there would be a ‘‘ready to use’’ standardized set
of outcomes for the condition under consideration (e.g.,
COVID-19 Core Outcomes initiative) [28]. When such a
set is not available, the guideline developers could rely
on previous prioritization efforts. For example, the Surviv-
ing Sepsis Campaign (SSC) guidelines on the management
of critically ill adults with COVID-19, instead of perform-
ing a new prioritization of outcomes, used the outcome pri-
oritization informed by the ongoing SSC guideline 2020
work and expert panel input [29]. The group could also rely
on outcomes prioritized for a similar disease (e.g., influenza
or severe acute respiratory syndrome [SARS]). In some ur-
gent situations, the group might opt to prioritize only one
critical outcome. For example, slowing the spread of the
pandemic (‘‘flattening the curve’’) was initially considered
as the sole critical outcome when considering public health
interventions for the COVID-19 pandemic.
Urgent situations are typically associated with scarcity
of data, particularly for clinical outcomes (e.g., clinical re-
covery). In such cases, the guideline developers might need
to rely on surrogate outcomes (e.g., viral load) for
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to inform other components of the PICO or PECO question.
For example, the National Institute for Health and Care
Excellence (NICE)’s ‘‘interim process and methods for
developing rapid guidelines on COVID-19’’ calls for using
information related to SARS, Middle East respiratory syn-
drome (MERS), and pandemic influenza [30].
It is important to determine a priori what indirect evi-
dence would be considered and used, if needed. Similar
key decisions in the design and conduct of the project
(e.g., eligibility criteria) should ideally be done a priori.
However, and given the limited time to fully consider the
different aspects of the project, post hoc decisions are more
likely in urgent compared with routine response when
developing guidelines.3.5. Collect the information needed
As mentioned earlier, the proposed approach considers
using existing guidelines and systematic reviews and does
not necessarily require the conduct of new rapid reviews.
NICE has adopted such an approach in its ‘‘interim process
and methods for developing rapid guidelines on COVID-
19’’ [29]. They aimed to reuse existing guidance as much
as possible, without conducting systematic literature
searches. They first searched for published guidance,
including WHO COVID-19 guidance, NICE guidance,
and guidance from professional organizations, both inside
and outside the UK [29]. If no guidance was identified, they
searched for and prioritized the following types of publica-
tions, in the following order: systematic reviews, random-
ized controlled trials, and published expert opinions.
Many organizations use a similar approach. For example,
in 2008, the European Food Safety Authority relied on a
previously published systematic review to develop its ur-
gent guidance related to the presence of melamine in com-
posite food products [31].
In addition to information about the health effects, the
guideline developers may need to identify contextual infor-
mation. In the example of mass evacuation in response to a
nuclear incident, there is a need to collect information
about the cost and feasibility of such a major undertaking,
as well as the acceptability by relevant stakeholders (e.g.,
governmental agencies, citizens). This information may
be available from administrative databases (e.g., for cost),
and through consulting with community leaders (e.g., to
assess the acceptability by stakeholders).
In terms of information sources, the published literature
may not be the only optimal source in urgent and rapidly
developing situations, like the COVID-19 pandemic. Infor-
mation sources may include preprint servers, open research
databases, and research data repositories. However, such
sources may not include conventional processes of peer re-
view and may require additional critical appraisal or
caution in the interpretation of the accuracy or stability of
the data. Specific to environmental exposure scenarios, itmay be important to evaluate or model the evidence for
health effects when little is known about the exposure
(e.g., a chemical with uncertain effects).3.6. Assess the adequacy of identified information
Once identified, the published literature (guidelines, sys-
tematic reviews, and if applicable, primary studies of any
design) needs to be assessed for ‘‘adequacy’’ based on
the three following criteria: relevance, credibility, and cur-
rency [32].
 Relevance or directness, according to GRADE termi-
nology [33], refers to the extent to which the popula-
tion, exposure/intervention, and outcomes identified
in the literature (whether for the original recommen-
dation or for the systematic reviews) reflect the ones
in the question being addressed by the recommenda-
tion. If any items are different enough that we would
expect different relative effects, then the evidence is
considered indirect.
 Credibility reflects the quality of conduct of the
guideline or of the systematic review being consid-
ered for use in the process of the urgent response.
There are a number of tools that could be used for
that purpose: the advancing guideline
development, reporting and evaluation in health care
II to assess the quality of conduct of guidelines
[34]; the assessment of multiple systematic reviews-
2 to assess the methodological quality of systematic
reviews [35], and ROBIS to assess the risk of bias
of systematic reviews [36].
 Currency or recency: although the currency of a sys-
tematic review depends on its search date, the cur-
rency of a guideline depends similarly to a large
extent on the search dates of the systematic reviews
used to inform recommendations. In some cases, even
if the search date is not current, a systematic review
may still be up to date if no new evidence was pub-
lished after the date of the search; however, a search
would need to be conducted to verify this assumption.
Rapidly updating a published systematic review may
be efficient, if that review is credible and new evi-
dence is known to have been published since the date
of the original search [37].
The guideline developers do not need to conduct the
above assessment for all identified relevant literature
(guidelines, systematic reviews, and primary studies). For
example, if they end up adopting an existing recommenda-
tion (addressed in step 6), although the recommendation
under consideration needs to be assessed, this would not
apply to all other identified literature (e.g., systematic re-
views and primary studies).
The adequacy of identified literature is not an ‘‘all or
none’’ assessment. For example, the guideline developer
might identify three potentially relevant systematic reviews.
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the three above criteria, but to different extents. We suggest
considering the criteria in the following order: relevance,
credibility, and currency. This means that the guideline de-
velopers would select a relevant but outdated systematic re-
view over an updated, but less relevant review. The idea is
that it is more efficient to ‘‘fix’’ the former review with a
quick update than to use the latter less relevant review.
During the 2014 Elk River chemical spill, the most rele-
vant information on the toxicology of the crude 4-
methylcyclohexanemethanol (MCHM) was obtained
directly from the manufacturer [38]. Within 6 days, the Sci-
entific Review Panel for the National Library of Medicine’s
Hazardous Substance Data Bank was able to expedite the
evaluation of the toxicology, chemical composition, and
chemical purpose to assess the credibility of the informa-
tion [38]. This early evaluation was a critical step in the
process of understanding the risks of exposure and the best
course of action for cleanup. However, additional research
was needed to better understand the short-term adverse
health effects associated with MCHM, and no additional in-
formation was available at the time. To expand the knowl-
edge base for MCHM and other chemicals associated with
the spill with the most current data, the Centers for Disease
Control and Prevention and the Agency for Toxic Sub-
stances Disease Registry enlisted the help of the National
Toxicology Program to conduct a series of short duration
studies [39]. The results obtained from these studies assis-
ted the West Virginia Bureau of Public Health in respond-
ing to public health concerns related to the MCHM and
other chemical exposures that occurred during the incident.
3.7. Develop the recommendations
Depending on the availability and adequacy of identified
literature (guidelines or systematic reviews), the guideline
developers may develop recommendations using one of
the four potential approaches: (1) adopt existing recom-
mendations; (2) adapt existing recommendations; (3)
develop new recommendations using existing systematic
and/or rapid reviews [15]; or (4) develop new recommenda-
tions using evidence provided by panelists (also referred to
as expert input or expert evidence) [40].
3.7.1. Adopt vs. adapt existing recommendations
The literature search may find an original recommenda-
tion that is ‘adequate’ for the urgent response, i.e., is rele-
vant, credible and current. At that point, the expert panel
group should decide whether to adopt the original recom-
mendation (i.e., use it as is) or adapt it. Practically, the
expert panel group ‘adopts’ a recommendation when it does
not change either the direction or the strength of that
recommendation. Otherwise, the recommendation is
‘adapted’.
To decide on adopting vs. adapting an original recom-
mendation, the expert panel group needs to assess whetherthe direction or the strength of recommendation may be
affected by any difference in the following factors (ideally
using a decision-making framework, e.g., EtD table) [21]:
 Rating of the importance of outcomes: a change in the
rating of the importance of outcomes might lead to a
change in the judgment of the balance of benefits and
harms. For example, an urgent response recommen-
dation addressing the use of invasive ventilation in
patients with COVID-19 might reflect a different pri-
oritization of the importance of ‘‘patient survival’’
outcome relative to ‘‘transmission of infection to
healthcare workers’’ outcome (in comparison to the
original recommendation) [41].
 Indirectness: what could have been judged as direct
evidence in the context of the original recommenda-
tion might be judged as indirect evidence in the ur-
gent response context (e.g., effectiveness of
treatment with corticosteroids among patients with
MERS-CoV vs. COVID-19) population. This might
lead to rating down the certainty of evidence. One
could use the GRADE framework to judge whether
that situation warrants rating down the certainty of
evidence for indirectness [33].
 Rating of evidence: the expert panel group may rate
the certainty of evidence differently than the original
recommendation for reasons other than indirectness
judgment (see above). Examples include different
judgment of the risk of bias or imprecision, and
consideration of new or emerging evidence.
 Baseline risks: the absolute reduction of an outcome
(e.g., mortality in laboratorians or other staff with a
potential occupational risk for Ebola receiving a
pre-exposure Ebola vaccination) might be higher or
lower in the context of the urgent response (e.g.,
Ebola outbreak responders) compared to context of
the original recommendation (e.g., due to a difference
in baseline risk of mortality between the two con-
texts). This could lead to a change in balance of ben-
efits and harms.
 Perspective: the original recommendation might have
been developed from an individual or clinical
perspective, while the urgent response has a popula-
tion or public health perspective. The new perspective
may broaden the relevant stakeholders (e.g., beyond
the patients, their caregivers, and healthcare pro-
viders), and increase the weight of EtD criteria such
as cost effectiveness and impact on equity.
 Contextual factors: the judgment on contextual fac-
tors (such as resource use, impact on equity, accept-
ability, and feasibility) might change when
considering the context of the rapid response (in com-
parison to the original context).
For each of the above factors, the judgment (between the
urgent guidance setting and the original one) needs to be
sufficiently different for panel members to adapt the
Fig. 2. Steps involved in developing a new recommendation using
panel input.
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The recommendation statement wording may be edited to
enhance the usability for the intended target group.
WHO developed interim guidance for the ‘‘clinical man-
agement of severe acute respiratory infection when
COVID-19 infection is suspected’’ in consultation with
the International Forum for Acute Care Trialists, Interna-
tional Severe Acute Respiratory and Emerging Infection
Consortium, and SSC [14]. Guideline developers originally
adapted this interim guidance from ‘‘Clinical management
of severe acute respiratory infection when Middle East res-
piratory syndrome coronavirus (MERS-CoV) infection is
suspected: interim guidance’’ [42]. In the first edition of
COVID-19 guidance, developers adopted many document
sections, research questions, and applicable guidance
verbatim, adapting some directives to reflect underlying un-
certainty about the microbiological profile of COVID-19
when informed from the indirect information from SARS
(caused by SARS-CoV1) and MERS (caused by MERS-
CoV) cases [14].
3.7.2. Develop new recommendation using existing
adequate systematic review
One other reasonable scenario would be to find an
adequate systematic review that would jump-start the
development of de novo recommendation(s). The develop-
ment would follow the standard GRADE evidence assess-
ment and recommendation development process with
some potential shortcuts to ensure the process is completed
within the desired timeframe [1].
The Infectious Diseases Society of America developed
rapid recommendations on the treatment and management
of hospitalized patients with COVID-19, including a
recommendation on corticosteroid treatment for hospital-
ized patients with acute COVID-19 [17]. At the time of
the first iteration of the guideline, the review team did not
identify any direct evidence to inform this recommenda-
tion; however, they identified a systematic review reporting
on corticosteroid use among patients with SARS-CoV-1 or
MERS-CoV [43]. The guideline panel determined this ex-
isting review to be direct enough to inform their
recommendation.
3.7.3. Develop new recommendation using expert panel
input
When no adequate recommendations are available for
adopting or adapting, and no adequate systematic reviews
are available to inform a de novo recommendation, using
expert panel input as the sole source of evidence is a
feasible alternative for an urgent response. It is important
to clarify that panel input is still important when developing
the recommendation based on existing recommendations or
systematic reviews.
Fig. 2 shows the steps involved in developing a new
recommendation using expert panel input. The panelists
are asked to review the literature they are provided withand then fill out a ‘‘panelist EtD’’ table [21]. In that table,
and in lieu of the systematically collected evidence, the
panelists provide a description of their ‘‘expert evidence’’
consisting of their observations and experiences (equivalent
to case reports and case series) [40]; these are expected to
reflect ‘‘facts’’ (as opposed to opinions). In the next step,
the steering group collates the input from all the panelists
and populates the EtD that will be used as the basis for
panel discussion and consensus building. Typically, the
panel chair builds consensus with the panelists through dis-
cussion, and if needed through (iterative) voting. Alterna-
tively, and for efficiency purposes, the chair can make
suggestions and have panelists agree or disagree with them;
however, caution is needed to ensure a broad range of per-
spectives is considered.
3.8. Consider an updating plan
Urgent situations are typically associated not only with
scarcity of data but also with rapidly developing evidence
base and contextual information. This raises the consider-
ation of establishing an updating plan, ideally through a
living process [8,44]. This is particularly relevant when
emerging data can potentially lead to a change in the
recommendation. The updating plan would need to define
the frequency of reassessment of the recommendation
(e.g., weekly, monthly), and to be adjusted to the speed
of development of the urgent situation and of the emer-
gence of the evidence.
In the case of an urgency related to an environmental
exposure, there might be a need to continuously monitor
9E.A. Akl et al. / Journal of Clinical Epidemiology 129 (2021) 1e11the level of exposure within the population of interest for
the purpose of triggering or updating the recommendations
[44]. In the example of the nuclear incident, regular collec-
tion of environmental radioactive iodine levels from the
field would be needed to reverse the recommendation for
mass evacuation.4. Discussion
Developing trustworthy guidelines in a relatively short
timeframe are of utmost importance but can be extraordi-
narily challenging. In this paper, we propose an approach
for developing trustworthy recommendations as part of an
urgent response (1e2 weeks). The approach offers the al-
ternatives of using existing guidelines to adopt or adapt rec-
ommendations; using existent systematic reviews to
develop new recommendations; and, when the previous op-
tions are not possible, relying on expert panel input to
develop new recommendations.
The alternatives of adopting, adapting, and using exis-
tent reviews to developing new recommendations are
similar to the ones proposed by the GRADE-
ADOLOPMENT methodology [45]. Although that method-
ology was designed to address guideline development pri-
marily to save and share resources, the approach
proposed in this paper is intended to address limited avail-
able time (and also potentially limited resources, recog-
nizing that the absence of guideline recommendations
may pose more of a threat than rapidly developed ones).
The alternative relying on expert panel input to
develop new recommendations might be perceived as
going against the principles of evidence-based medicine.
However, Schunemann et al. [40] argued that expert
opinion can be considered as ‘‘expert evidence.’’ They
did caution however against confusing expert evidence
with expert’s views and judgments. Similarly, Djulbe-
govic and Guyatt [46] refer to the ‘‘experience of individ-
ual clinicians’’ as a type of evidence. They also make the
point that evidence requires interpretation and ‘‘a
consensus process must determine that interpretation’’
in the context of guidelines.
Although we may not have captured all situations unique
to creating urgent responses, we have prioritized providing
a broad, structured, and pragmatic approach. The illustra-
tive examples exemplify how a number of guideline organi-
zations had to rapidly react to urgent situations related to
environmental exposures or to the COVID-19 pandemic.
Many of the examples highlight how flexibility was needed
on the side of the developer in terms of maintaining trust-
worthy methodology.
Having recommendations for situations that might recur
on an urgent basis may reduce the need for development of
recommendations within urgent timeframes. For example,
Public Health England has existing guidelines for handling
nuclear incidents that are regularly updated, so that thismaterial is available in advance of catastrophic events
[47]. Nevertheless, there will continue to be new unex-
pected incidents that require decisions to be made for
which no relevant recommendations are already available
or could have been foreseen. In these instances, it is crit-
ical to leverage collaborations, capabilities, and resources
that allow for rapid assessment of adequate information to
support recommendation development. Moreover, it would
be important for coordinated efforts by guideline devel-
opers to avoid duplication of efforts and sometimes incon-
sistent or even contradictory recommendations.Acknowledgments
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